Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus

Therapeutic Drug Monitoring

Volumn 33, Issue 5, 2011, Pages 658-662

  Fukuda, Tsuyoshi ^a,b   Brunner, Hermine I ^a,b   Sagcal Gironella, Anna Carmela P ^a   Vinks, Alexander A ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

multidrug resistance associated protein 2; mycophenolic acid; nonsteroidal anti inflammatory drug; pediatric patient; pharmacokinetics; SLE

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD ONSET SYSTEMIC LUPUS ERYTHEMATOSUS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; ENTEROHEPATIC CIRCULATION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENTEROHEPATIC CIRCULATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYCOPHENOLIC ACID;

EID: 84860413512     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318228195f     Document Type: Article

References (10)

1. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455. (Pubitemid 28273453)
2. Kuypers DR, Vanrenterghem Y, Squifflet JP, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit. 2003;25:609-622. (Pubitemid 37238896)
3. Sagcal-Gironella AC, Fukuda T, Wiers K, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthr Rheum. 2011;40:307-313.
4. Baldelli S, Merlini S, Perico N, et al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007;8:1127-1141. (Pubitemid 47578222)
5. Naesens M, Kuypers DR, Verbeke K, et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation. 2006;82: 1074-1084. (Pubitemid 44632124)
6. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987-994. (Pubitemid 40571246)
7. Braun F, Schocklmann H, Ziegler E, et al. Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics. Clin Pharmacol Ther. 2009;86:411-415.
8. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, et al. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2-and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007;320:229-235. (Pubitemid 46025738)
9. Sherwin CM, Fukuda T, Brunner HI, et al. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011;50:1-24.
10. Fukuda T, Goebel J, Thogersen H, et al. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J Clin Pharmacol. 2011;51:309-320.